Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Silo PharmaNasdaq: SILO

2 Drug Candidates

US-listed clinical-stage biotech developing psychedelic and ketamine-based therapies for PTSD and chronic pain. SPC-15 is an intranasal 5-HT4 serotonin receptor agonist for PTSD in IND-enabling GLP studies. SP-26 is a proprietary ketamine implant for fibromyalgia being co-developed with the University of Maryland.

Drug Pipeline

2

SPC-15

Pre-clinical
PTSD

Intranasal 5-HT4 serotonin receptor agonist for PTSD. IND-enabling GLP (good laboratory practice) studies commenced March 2025.

Pre-clinical
Fibromyalgia

Proprietary ketamine implant for fibromyalgia. Co-developed with the University of Maryland.

Quick Facts

Type
Public Biotech
Ticker
Nasdaq: SILO
Lead Stage
Pre-clinical
Website
Visit